

Correction to Consolidation Timetable - Notice of General Meeting

Sydney, Australia – 3 February 2015: Medibio Limited (**MEB or the Company**) advises that the notice of meeting dispatched by the Company dated 2 February 2015 for the meeting to be held on 6 March 2015 contained incorrect dates for the consolidation timetable.

Under section 2.2 (page 15) the following amendments are made to the indicative timetable:

Event	Date
Execution of Invatec SPA's	28 January 2015
Dispatch of Notice of Meeting	2 February 2015
General Meeting	6 March 2015
First date for Company to send notices to security holders of change of holdings as a result of the MEB Share Consolidation	16 March 2015
Last day for Securities to be entered into holders' security holdings and for Company to send holding statements out to each security holder – Post-consolidation Basis	20 March 2015
Settlement of Proposed Transaction – issue of Consideration Shares and Placement Shares	21 March 2015
Holding Statements sent out – Placement	27 March 2015

Under section 12.10(e) (page 46) the following amendments are made to the consolidation timetable:

Event	Date
General Meeting to approve MEB Share Consolidation	6 March 2015
Company advises the ASX that MEB Shareholders have approved MEB Share Consolidation	6 March 2015
Last day for pre-consolidation trading	10 March 2015
Trading on a deferred settlement basis starts*	11 March 2015
Last day to register transfers on a pre-consolidation basis	13 March 2015
First day for Company to send notice to the Shareholders of change of holdings as a result of reorganisation First day for Company to register securities on a post-consolidation Basis and for issue of holding statements	16 March 2015
Issue date Deferred settlement market ends Last day for securities to be entered into the holders' security holdings and for Company to send notice to each security holder	20 March 2015

End

About Medibio Limited

Medibio (ASX: MEB) is a medical technology company developing a new diagnostic test for depression and other mental health disorders. This test is based on measured differences in circadian heart rate and measures of heart rate variability. The technology is based on the discovery that circadian heart rates are sensitive measures for depression and other mental health disorders. The technology consists of a heart monitor that sends recordings wirelessly to the internet where a proprietary algorithm analyses and delivers a quantifiable diagnosis. The Technology has the potential to be the first FDA-approved objective, evidence based approach to the diagnosis of depression and other affective disorders. The technology has already benefited from 10 years of laboratory research. Medibio is undertaking pivotal studies to validate its clinical utility with the Johns Hopkins University School of Medicine and the Black Dog Institute.

Further Information contact:	
Kris Knauer Executive Director/CEO: Medibio Limited kris.knauer@Medibio.com.au T: +61 (0) 411 885 979	